BIVI

MKT CAP:$11M

BioVie Inc.

Market Cap

$11M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.42+$0.09 (+6.77%)

Apr 24, 2026

Company Details

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for...

CEO

Cuong Viet Do

IPO Date

Sep 18, 2020

Website

bioviepharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$17M

EPS (Diluted)

-$5.07

Free Cash Flow

-$14M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2026

May 11, 2026

PENDING

Q2 2026

Feb 6, 2026

$0EPS -$0.77

Q1 2026

Nov 10, 2025

$0EPS -$0.98

FY 2025

Aug 15, 2025

$0EPS -$12.12

Q4 2025

Aug 15, 2025

$0EPS -$1.82

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 22	$0	-$57.3K	-$6M
Q4 22	$0	$0	-$9M
Q1 23	$0	$0	-$9M
Q2 23	$0	$0	-$11M
Q3 23	$0	$0	-$14M
Q4 23	$0	$0	-$11M
Q1 24	$0	$0	-$11M
Q2 24	$0	$0	-$9M
Q3 24	$0	$0	-$8M
Q4 24	$0	-$57.3K	-$5M
Q1 25	$0	$0	-$4M
Q2 25	$0	$0	-$7M
Q3 25	$0	$0	-$3M
Q4 25	$0	-$57.3K	-$4M
Q1 26	$0	-$57.3K	-$5M
Q2 26	$0	-$57.3K	-$6M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$6M	-$6M
Q4 22	-$6M	-$6M
Q1 23	-$9M	-$9M
Q2 23	-$8M	-$8M
Q3 23	-$12M	-$12M
Q4 23	-$11M	-$11M
Q1 24	-$12M	-$12M
Q2 24	-$6M	-$6M
Q3 24	-$6M	-$6M
Q4 24	-$4M	-$4M
Q1 25	-$4M	-$4M
Q2 25	-$9M	-$9M
Q3 25	-$1M	-$1M
Q4 25	-$6M	-$6M
Q1 26	-$3M	-$3M
Q2 26	-$4M	-$4M

Capital Expenditures

Quarter	CapEx
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0
Q1 26	$0
Q2 26	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	—	+87.7%
Q4 22	—	+209.6%
Q1 23	—	+59.3%
Q2 23	—	+72.5%
Q3 23	—	+139.6%
Q4 23	—	+18.1%
Q1 24	—	+23.1%
Q2 24	—	-23.6%
Q3 24	—	-43.9%
Q4 24	—	-56.4%
Q1 25	—	-62.1%
Q2 25	—	-17.0%
Q3 25	—	-61.4%
Q4 25	—	-23.5%
Q1 26	—	+28.2%
Q2 26	—	-14.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$930.3K	—
Q4 22	$2M	—
Q1 23	$896.2K	—
Q2 23	$3M	—
Q3 23	$906.5K	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$922.9K	—
Q3 24	$1M	—
Q4 24	$1M	—
Q1 25	$453.8K	—
Q2 25	$651.0K	—
Q3 25	-$192.3K	—
Q4 25	$683.2K	—
Q1 26	$0	—
Q2 26	$486.7K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 22	$4M	—	$2M
Q4 22	$6M	—	—
Q1 23	$7M	—	—
Q2 23	$7M	—	—
Q3 23	$11M	—	$3M
Q4 23	$8M	—	—
Q1 24	$9M	—	$2M
Q2 24	$6M	—	—
Q3 24	$6M	—	—
Q4 24	$2M	—	$3M
Q1 25	$2M	—	—
Q2 25	$5M	—	—
Q3 25	$1M	—	—
Q4 25	$1M	—	$2M
Q1 26	$3M	$2M	—
Q2 26	$4M	$2M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$25M	$0	$25M
Q4 22	$19M	$0	$19M
Q1 23	$21M	$0	$21M
Q2 23	$46M	$0	$46M
Q3 23	$31M	$13M	$44M
Q4 23	$19M	$14M	$34M
Q1 24	$21M	$0	$21M
Q2 24	$20M	$0	$20M
Q3 24	$30M	$0	$30M
Q4 24	$24M	$0	$24M
Q1 25	$20M	$0	$20M
Q2 25	$24M	$0	$24M
Q3 25	$23M	$0	$23M
Q4 25	$18M	$0	$18M
Q1 26	$25M	$0	$25M
Q2 26	$21M	$0	$21M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 22	250K	-90.0%	+79.5%
Q4 22	250K	+0.0%	-82.1%
Q1 23	3M	+989.2%	+14.7%
Q2 23	3M	+14.5%	+24.9%
Q3 23	4M	+13.3%	+1313.9%
Q4 23	363K	-89.7%	+45.2%
Q1 24	4M	+912.2%	+35.0%
Q2 24	4M	+3.9%	+22.5%
Q3 24	448K	-88.3%	-87.3%
Q4 24	611K	+36.5%	+68.5%
Q1 25	640K	+4.7%	-82.6%
Q2 25	2M	+145.6%	-58.8%
Q3 25	2M	+17.8%	+313.1%
Q4 25	15M	+698.3%	+2316.7%
Q1 26	5M	-64.7%	+715.0%
Q2 26	8M	+51.9%	+404.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 22	$0	15
Q4 22	$0	13
Q1 23	$0	13
Q2 23	$0	13
Q3 23	$0	13
Q4 23	$0	18
Q1 24	$0	18
Q2 24	$0	18
Q3 24	$0	18
Q4 24	$0	14
Q1 25	$0	14
Q2 25	$0	14
Q3 25	$0	14
Q4 25	$0	13
Q1 26	$0	13
Q2 26	$0	13

Revenue / Employee